Company profile: Quantum Surgical
1.1 - Company Overview
Company description
- Provider of robotic-assisted interventional oncology solutions for minimally invasive liver cancer treatment, including Epione for planning, targeting, delivery and confirmation of tumor ablation; CT/MRI fusion-based multimodal planning; real-time respiratory monitoring; post-ablation margin verification; and robotic guidance with navigation and haptics (6 DOF) for precise targeting and safe needle release.
Products and services
- Epione: A robotic-assisted, clinical-grade system that architects planning, targeting, delivering, and confirming tumor ablation in interventional oncology, coordinating the entire process from pre-planning through post-ablation confirmation
- Robotic Guidance with Navigation & Haptics: An industrial-grade guidance component delivering 6 degrees of freedom for precise targeting and quick, safe needle release with navigation and haptics during tumor ablation
- Multimodal Planning: A medical-grade imaging workflow that fuses CT and MRI images to enhance tumor visualization for treatment planning, sharpening lesion delineation prior to ablation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Quantum Surgical
GPC Biotech
HQ: Germany
Website
- Description: Provider of anticancer drug discovery and development as a German biopharmaceutical company. Portfolio includes Satraplatin, a platinum-based small molecule for prostate cancer; MAb 1D09C3, a monoclonal antibody for lymphoma; and RGB-286199, a small molecule for refractory cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GPC Biotech company profile →
Shorla Oncology
HQ: Ireland
Website
- Description: Provider of innovative oncology drugs focused on women's and pediatric cancers, developing and commercializing life-saving treatments that address unmet needs. Portfolio includes FDA-approved JYLAMVO (oral methotrexate) and TEPYLUTE for breast and ovarian cancer, as well as a Nelarabine Injection; pipeline programs include SH-201 under FDA review and SH-110 in development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Shorla Oncology company profile →
Sanarus
HQ: United States
Website
- Description: Provider of minimally invasive devices for the diagnosis and treatment of breast tumors, including the Visica treatment system for cryoablation of breast fibroadenomas; the Cassi II rotational core biopsy system, an automated hand held breast biopsy device to secure contiguous biopsy samples; and the ImarC tissue marker system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sanarus company profile →
Arthrosi Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology drug discovery and development, focused on AR882, a uricosuric therapy in development for gout to lower serum urate levels, reduce flares, and resolve tophi, with efficacy and safety demonstrated in clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arthrosi Therapeutics company profile →
Oncovision
HQ: Mexico
Website
- Description: Provider of molecular vision solutions for the health sciences sector, supporting cancer diagnosis and treatment and advanced research in neurology, oncology, and cardiology. Spanish technology start-up founded in 2003 by the Corpuscular Physics Institute (CSIC) and the University of Valencia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncovision company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Quantum Surgical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Quantum Surgical
2.2 - Growth funds investing in similar companies to Quantum Surgical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Quantum Surgical
4.2 - Public trading comparable groups for Quantum Surgical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →